Trial Profile
Randomized Phase II Study of S-1 (SOX) or Capecitabine (XELOX) in Combination With Oxaliplatin in Patients With Recurrent or Metastatic Gastric Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 11 Jan 2012 Results published in the European Journal of Cancer.
- 11 Jan 2012 Status changed from recruiting to active, no longer recruiting.
- 02 Oct 2009 New trial record